AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3937970 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy A (vincristine/ifosfamide/tegafur)
Number of subjects: 109
Study 3937970 — intervention group
Group type: COMPARATOR
Intervention: Therapy B (fluorouracil/trofosfamide/methotrexate/melphalan)
Number of subjects: 109
Study 30915778 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only (Group 1, n = 21)
Number of subjects: 43
Study 30915778 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + myo-inositol (MI) 4 g + folic acid 400 µg daily (Group 2, n = 10)
Number of subjects: 43
Study 30915778 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + MI 1.1 g + D-chiro-inositol (DCI) 27.6 mg + folic acid 400 µg daily (Group 3, n = 13)
Number of subjects: 43
Study 29913017 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX002 (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 10 mg/kg, 30 mg/kg, or 60 mg/kg)
Number of subjects: 80
Study 29913017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26265098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 2.5 mg administered every 12 hours for 4.5 days
Number of subjects: 0
Study 26265098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg administered every 12 hours for 4.5 days
Number of subjects: 0
Study 26265098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg administered every 12 hours for 4.5 days
Number of subjects: 0
Study 26265098 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine data analysis
Number of subjects: 0
Study 25277543 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care C-reactive protein test and/or brief intervention with safety net advice
Number of subjects: 2560
Study 25277543 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 2560
Study 22193780 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance + impact exercise program
Number of subjects: 106
Study 22193780 — intervention group
Group type: COMPARATOR
Intervention: Stretching placebo program
Number of subjects: 106
Study 19129262 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour modification intervention
Number of subjects: 205
Study 19129262 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study 17187965 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg modafinil
Number of subjects: 15
Study 17187965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15166843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 15166843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation strategies (low tidal volumes, PEEP)
Number of subjects: 0
Study 15166843 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 0
Study 15166843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 0
Study 15166843 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 0
Study 15166843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 0
Study 11782664 — intervention group
Group type: EXPERIMENTAL
Intervention: Artistic gymnasts
Number of subjects: 17
Study 11782664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic gymnasts
Number of subjects: 17
Study 11782664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gymnasts (artistic and rhythmic)
Number of subjects: 17
Study 11782664 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study 10621863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 35
Study 10621863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10621863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results
Number of subjects: 35
Study 7865087 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I - oral hygiene training program based on self-diagnosis and the 'linking method'; 20 minutes sessions at two-day intervals for the first three visits, followed by monthly check-ups for 4 months and then every 3 months for reevaluation.
Number of subjects: 222
Study 7865087 — intervention group
Group type: COMPARATOR
Intervention: Group II - detailed oral hygiene instruction on cleaning every tooth surface using dental tape, toothbrush, and fluoride dentifrice; same recall intervals as Group I.
Number of subjects: 222
Study 7865087 — intervention group
Group type: COMPARATOR
Intervention: Control Group III - no specific intervention mentioned; standard care.
Number of subjects: 222
Study 2659293 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam 1 g/day intramuscularly
Number of subjects: 186
Study 2659293 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 80 mg i.m. twice daily
Number of subjects: 186
Study 30192329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anesthetic (ropivacaine 100 mg bolus pre- and post-dissection, 20 mg/h continuous infusion for 48 hours)
Number of subjects: 86
Study 30192329 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline equivalent)
Number of subjects: 86
Study 27435972 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg/day
Number of subjects: 1331
Study 27435972 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg/day
Number of subjects: 1331
Study 24683916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 222
Study 24683916 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (Control)
Number of subjects: 222
Study 24683916 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 222
Study 23884802 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum cementless tibial component (Group 1)
Number of subjects: 145
Study 23884802 — intervention group
Group type: COMPARATOR
Intervention: Cemented conventional tibial component (Group 2)
Number of subjects: 145
Study 20845225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for schizophrenia, duration 12 weeks, assessed through 15-min semistructured interviews and APES ratings.
Number of subjects: 0
Study 18362865 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 gel 0.1%, 0.25%, 1.0%
Number of subjects: 48
Study 18362865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0%)
Number of subjects: 48
Study 18362865 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 gel 1%
Number of subjects: 48
Study 18362865 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 gel (all concentrations)
Number of subjects: 48
Study 16980315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 160)
Number of subjects: 241
Study 16980315 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 81)
Number of subjects: 241
Study 12684358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 60) received detailed advice on achieving a weight reduction of 10% or more through a low‐energy Mediterranean‐style diet and increased physical activity.
Number of subjects: 120
Study 12684358 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 60) was given general information about healthy food choices and exercise.
Number of subjects: 120
Study 11079860 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEVAL computerized home-based physical therapy intervention
Number of subjects: 0
Study 9240868 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section performed prior to labour
Number of subjects: 0
Study 9240868 — intervention group
Group type: COMPARATOR
Intervention: Routine vaginal delivery
Number of subjects: 0
Study 1524994 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with monitoring of white blood cell counts (WBC) and absolute neutrophil counts (ANC)
Number of subjects: 52
Study 1524994 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with monitoring of WBC and ANC
Number of subjects: 52
Study 3888726 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ibuprofen/kg body-weight
Number of subjects: 44
Study 3888726 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ibuprofen/kg body-weight
Number of subjects: 44
Study 31587925 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood TNF expression and serum TNF‐α levels
Number of subjects: 0
Study 31587925 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 0
Study 29509769 — intervention group
Group type: EXPERIMENTAL
Intervention: Information framed as a gain
Number of subjects: 722
Study 29509769 — intervention group
Group type: EXPERIMENTAL
Intervention: Information framed as a loss
Number of subjects: 722
Study 29509769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 722
Study 29509769 — intervention group
Group type: EXPERIMENTAL
Intervention: Information intervention (pooled groups)
Number of subjects: 722
Study 29509769 — intervention group
Group type: EXPERIMENTAL
Intervention: Information framed as a loss vs. information framed as a gain
Number of subjects: 722
Study 27497037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fused, colorized diffusion weighted imaging (DWI) and anatomic T2 images
Number of subjects: 20
Study 27497037 — intervention group
Group type: COMPARATOR
Intervention: Routine contrast-enhanced T1 images
Number of subjects: 20
Study 25217858 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare PRO
Number of subjects: 47
Study 25217858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono‐Pen
Number of subjects: 47
Study 23118244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education pamphlet
Number of subjects: 36
Study 23118244 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 36
Study 20472299 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (up to 20mg)
Number of subjects: 40
Study 20472299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18593651 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vital-capacity breathing with 7.2% inspiratory sevoflurane in 6 L/min oxygen followed by assisted ventilation with 3.5% sevoflurane for 4.5 minutes.
Number of subjects: 36
Study 18593651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 µg/kg pretreatment before induction.
Number of subjects: 36
Study 18593651 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation with 3.5% sevoflurane for 4.5 minutes.
Number of subjects: 36
Study 16442890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) combined with optimal medical treatment
Number of subjects: 500
Study 16442890 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment alone
Number of subjects: 500
Study 16442890 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT
Number of subjects: 500
Study 14617231 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily BIAsp30
Number of subjects: 403
Study 14617231 — intervention group
Group type: COMPARATOR
Intervention: Twice daily NPH insulin
Number of subjects: 403
Study 11855033 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the health focused study abroad program
Number of subjects: 17
Study 11855033 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not participate in the tour)
Number of subjects: 17
Study 8837118 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-mastectomy radiotherapy with adjuvant chemotherapy
Number of subjects: 0
Study 8837118 — intervention group
Group type: COMPARATOR
Intervention: Obsolete radiotherapy techniques
Number of subjects: 0
Study 1364937 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets (ECT)
Number of subjects: 39
Study 1364937 — intervention group
Group type: COMPARATOR
Intervention: Plain naproxen tablets (PT)
Number of subjects: 39
Study 3989392 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with a polyunsaturated to saturated fat (P/S) ratio of 0.9 (group I)
Number of subjects: 40
Study 3989392 — intervention group
Group type: COMPARATOR
Intervention: Diet with a polyunsaturated to saturated fat (P/S) ratio of 0.4 (group II)
Number of subjects: 40
Study 3989392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 40
Study 31464476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral exogenous progesterone (200 mg twice per day)
Number of subjects: 47
Study 31464476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31504118 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Number of subjects: 122
Study 31504118 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib + E/P
Number of subjects: 122
Study 28747330 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein load of 30 g (120 kcal)
Number of subjects: 16
Study 28747330 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein load of 70 g (280 kcal)
Number of subjects: 16
Study 28747330 — intervention group
Group type: COMPARATOR
Intervention: Flavored water control drink (0 kcal)
Number of subjects: 16
Study 28747330 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (both doses)
Number of subjects: 16
Study 25709076 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic prompt
Number of subjects: 437
Study 25709076 — intervention group
Group type: COMPARATOR
Intervention: Control (no electronic prompt)
Number of subjects: 437
Study 25709076 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of all studies
Number of subjects: 437
Study 23437787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation catheter with 6 distal irrigation channels (6C)
Number of subjects: 296
Study 23437787 — intervention group
Group type: COMPARATOR
Intervention: Ablation catheter with 12 distal irrigation channels (12C)
Number of subjects: 296
Study 21475949 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (Alf) for 8 weeks
Number of subjects: 100
Study 21475949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (Tam) for 8 weeks
Number of subjects: 100
Study 21475949 — intervention group
Group type: COMPARATOR
Intervention: Alfuzosin (Alf) after Tamsulosin (Tam)
Number of subjects: 100
Study 21475949 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (Tam) after Alfuzosin (Alf)
Number of subjects: 100
Study 18353696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained-release morphine (60 mg)
Number of subjects: 108
Study 18353696 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (0.6 mg, 25 microg/h)
Number of subjects: 108
Study 18353696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methadone (15 mg)
Number of subjects: 108
Study 16084579 — intervention group
Group type: EXPERIMENTAL
Intervention: phonological rhyme generation paradigm
Number of subjects: 19
Study 16084579 — intervention group
Group type: COMPARATOR
Intervention: classical word generation condition
Number of subjects: 19
Study 15365277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy including diuretics and agents that block angiotensin II
Number of subjects: 0
Study 15365277 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 15365277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination drug therapy
Number of subjects: 0
Study 11505794 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of somatropin (8.64 IU)
Number of subjects: 13
Study 11505794 — intervention group
Group type: COMPARATOR
Intervention: Cannula injection of somatropin (8.64 IU)
Number of subjects: 13
Study 9284488 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid meal
Number of subjects: 10
Study 9284488 — intervention group
Group type: COMPARATOR
Intervention: Liquid meal
Number of subjects: 10
Study 9284488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 10
Study 9284488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 10
Study 9284488 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 10
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (12 g/m2)
Number of subjects: 0
Study 7682088 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (6 g/m2)
Number of subjects: 0
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 0
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (added to chemotherapy)
Number of subjects: 0
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial cisplatinum
Number of subjects: 0
Study 7682088 — intervention group
Group type: COMPARATOR
Intervention: Limb-salvage procedures
Number of subjects: 0
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative postsurgical chemotherapy for poor responders
Number of subjects: 0
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sequelae of chemotherapy
Number of subjects: 0
Study 7682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of drug administration methods
Number of subjects: 0
Study 3803252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g every 12 hours for 10 days
Number of subjects: 103
Study 3803252 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg every 8 hours for 10 days
Number of subjects: 103
Study 31067018 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute one-to-one structured brief intervention with a trained learning mentor and an alcohol leaflet
Number of subjects: 443
Study 31067018 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle leaflet (no alcohol information)
Number of subjects: 443
Study 31067018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 443
Study 31067018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the brief intervention
Number of subjects: 443
Study 29493785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous suturing (IC)
Number of subjects: 339
Study 29493785 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous suturing (TC)
Number of subjects: 339
Study 27137950 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training (4, 2-min unilateral contractions at 30% of maximal voluntary contraction, 3 days per week for 8 weeks)
Number of subjects: 20
Study 27137950 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 24886064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.4 mg/kg (single bolus)
Number of subjects: 0
Study 24886064 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes)
Number of subjects: 0
Study 22192144 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8309
Number of subjects: 18
Study 22192144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/d)
Number of subjects: 108
Study 20430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d)
Number of subjects: 108
Study 20430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and valsartan
Number of subjects: 108
Study 17663296 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week combined dietary-behavioral-physical activity intervention
Number of subjects: 54
Study 16059623 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 4011
Study 16059623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4011
Study 11966765 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 68
Study 11966765 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of HAART
Number of subjects: 68
Study 10425465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol and norethisterone
Number of subjects: 14
Study 10425465 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral oestradiol and norethisterone
Number of subjects: 14
Study 10425465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol
Number of subjects: 14
Study 8869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (c7E3) administered at the time of angioplasty or directional coronary atherectomy
Number of subjects: 0
Study 8869018 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 8869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (c7E3)
Number of subjects: 0
Study 2406891 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Proximal Vagotomy (SPV)
Number of subjects: 60
Study 2406891 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Proximal Vagotomy + Pyloroplasty (SPV + PP)
Number of subjects: 60
Study 2406891 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study 2406891 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomized patients
Number of subjects: 60
Study 7467371 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoket-spray (3.75 mg)
Number of subjects: 40
Study 7467371 — intervention group
Group type: COMPARATOR
Intervention: Placebo-spray
Number of subjects: 40
Study 30875097 — intervention group
Group type: EXPERIMENTAL
Intervention: NSS powder (1 g/day)
Number of subjects: 30
Study 30875097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30400846 — intervention group
Group type: EXPERIMENTAL
Intervention: Close contact experience with individuals with mental illness
Number of subjects: 1002
Study 30400846 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-close contact experience with individuals with mental illness
Number of subjects: 1002
Study 30400846 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreeableness and openness to experience
Number of subjects: 1002
Study 30400846 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraversion
Number of subjects: 1002
Study 30400846 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness and neuroticism
Number of subjects: 1002
Study 30400846 — intervention group
Group type: EXPERIMENTAL
Intervention: Openness to experience
Number of subjects: 1002